Pubblicazioni

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

2023 - THE LANCET

Verstovsek, Srdan; Gerds, Aaron T; Vannucchi, Alessandro M; Al-Ali, Haifa Kathrin; Lavie, David; Kuykendall, Andrew T; Grosicki, Sebastian; Iurlo, Alessandra; Goh, Yeow Tee; Lazaroiu, Mihaela C; Egyed, Miklos; Fox, Maria Laura; Mclornan, Donal; Perkins, Andrew; Yoon, Sung-Soo; Gupta, Vikas; Kiladjian, Jean-Jacques; Granacher, Nikki; Lee, Sung-Eun; Ocroteala, Luminita; Passamonti, Francesco; Harrison, Claire N; Klencke, Barbara J; Ro, Sunhee; Donahue, Rafe; Kawashima, Jun; Mesa, Ruben; Martelli, Maurizio

Impact of donor-derived CD34+infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT

2022 - BONE MARROW TRANSPLANTATION

Czerw, T; Iacobelli, S; Malpassuti, V; Koster, L; Kroger, N; Robin, M; Maertens, J; Chevallier, P; Watz, E; Poire, X; Snowden, Ja; Kuball, J; Kinsella, F; Blaise, D; Remenyi, P; Mear, Jb; Cammenga, J; Rubio, Mt; Maury, S; Daguindau, E; Finnegan, D; Hayden, P; Hernandez-Boluda, Jc; Mclornan, D; Yakoub-Agha, I